trending Market Intelligence /marketintelligence/en/news-insights/trending/az9G5YE5xT1INRcQmkSJQA2 content esgSubNav
In This List

Heat Biologics closes common stock offering

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Heat Biologics closes common stock offering

Heat Biologics Inc. closed its underwritten public offering of 5 million common shares at 80 cents apiece.

The offering generated gross proceeds of $4 million.

Underwriters in the transaction have the option to buy up to an additional 750,000 shares.

Heat Biologics plans to use the net proceeds to fund preclinical and clinical programs; for working capital and general corporate purposes; and to acquire, license or invest in complementary businesses, technologies, product candidates or other intellectual property.

Aegis Capital Corp. acted as the sole book-running manager for the offering.